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DOI 10.1186/s12974-015-0273-0RESEARCH Open AccessCannabidiol, a non-psychoactive cannabinoid,
leads to EGR2-dependent anergy in activated
encephalitogenic T cells
Ewa Kozela1*, Ana Juknat1, Nathali Kaushansky2, Avraham Ben-Nun3, Giovanni Coppola4 and Zvi Vogel1,2Abstract
Background: Cannabidiol (CBD), the main non-psychoactive cannabinoid, has been previously shown by us to
ameliorate clinical symptoms and to decrease inflammation in myelin oligodendrocyte glycoprotein
(MOG)35-55-induced mouse experimental autoimmune encephalomyelitis model of multiple sclerosis as well as to
decrease MOG35-55-induced T cell proliferation and IL-17 secretion. However, the mechanisms of CBD
anti-inflammatory activities are unclear.
Methods: Here we analyzed the effects of CBD on splenocytes (source of accessory T cells and antigen
presenting cells (APC)) co-cultured with MOG35-55-specific T cells (TMOG) and stimulated with MOG35-55. Using
flow cytometry, we evaluated the expression of surface activation markers and inhibitory molecules on T cells
and B cells. TMOG cells were purified using CD4 positive microbead selection and submitted for quantitative PCR
and microarray of mRNA transcript analyzes. Cell signaling studies in purified TMOG were carried out using
immunoblotting.
Results: We found that CBD leads to upregulation of CD69 and lymphocyte-activation gene 3 (LAG3) regulatory
molecules on CD4+CD25− accessory T cells. This subtype of CD4+CD25−CD69+LAG3+ T cells has been
recognized as induced regulatory phenotype promoting anergy in activated T cells. Indeed, we observed that
CBD treatment results in upregulation of EGR2 (a key T cell anergy inducer) mRNA transcription in stimulated
TMOG cells. This was accompanied by elevated levels of anergy promoting genes such as IL-10
(anti-inflammatory cytokine), STAT5 (regulatory factor), and LAG3 mRNAs, as well as of several enhancers of cell
cycle arrest (such as Nfatc1, Casp4, Cdkn1a, and Icos). Moreover, CBD exposure leads to a decrease in STAT3
and to an increase in STAT5 phosphorylation in TMOG cells, positive and negative regulators of Th17 activity,
respectively. In parallel, we observed decreased levels of major histocompatibility complex class II (MHCII), CD25,
and CD69 on CD19+ B cells following CBD treatment, showing diminished antigen presenting
capabilities of B cells and reduction in their pro-inflammatory functions.
Conclusions: Our data suggests that CBD exerts its immunoregulatory effects via induction of CD4+CD25−CD69+LAG3+
cells in MOG35-55-activated APC/TMOG co-cultures. This is accompanied by EGR2-dependent anergy of stimulated TMOG
cells as well as a switch in their intracellular STAT3/STAT5 activation balance leading to the previously observed decrease
in Th17 activity.
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Cannabinoids, the active materials found in Cannabis
preparations (for example, in marijuana), have been shown
to exert potent immunomodulatory and anti-inflammatory
activities in various animal models of diseases with
inflammatory background, including rheumatoid arthritis,
experimental colitis, liver inflammation, brain injury, neu-
rodegeneration, and multiple sclerosis (MS) (reviewed by
[1,2]). MS is a neurodegenerative inflammatory disease of
unknown trigger and complex neuroimmune pathology
that involves myelin degeneration and CNS dysfunction.
Encephalitogenic T cells specific for myelin components
(primed by antigen presenting cells (APC)) have a key role
in MS pathology [3,4] as well as in the mouse experimental
autoimmune encephalomyelitis (EAE) model of MS [5].
We and others have shown that several cannabinoids in-
cluding the main psychoactive Δ-9-tetrahydrocannabinol
(THC) [6,7] and the main non-psychoactive cannabinoid,
cannabidiol (CBD) [8] ameliorate CNS neuroinflammation
and demyelination in EAE. Moreover, we have shown
recently that CBD and THC decrease the myelin oligo-
dendrocyte glycoprotein (MOG)35-55-induced T cell
proliferation as well as the secretion of IL-17 and IL-6
cytokines [9], the key autoimmune cytokines that de-
fine the Th17 pathogenic phenotype [10,11]. Moreover,
CBD increases the production of the anti-inflammatory IL-
10 cytokine in these MOG35-55-stimulated T cells [9].
T cell effector functions and tolerance are controlled
through multiple signaling pathways regulated by interac-
tions with APC (and other accessory immune cells) and
their surface molecules. Among the molecules shown to
regulate memory T cell function, lymphocyte-activation
gene 3 (LAG3; CD223) and CD69 have gained a major
interest. LAG3 is a CD4 homolog that by interfering with
major histocompatibility complex class II (MHCII) on
APC upon antigen exposure [12] inhibits the function and
expansion of memory T cells [13-15]. Furthermore, LAG3
upregulation induces early growth response 2 (EGR2)-
dependent anergy (exhaustion) of activated T cells, this
way limiting their pathogenic activity [16,17]. CD69 is
a very potent inhibitory co-receptor that was found to
serve as a constitutive suppressor of Th17 differenti-
ation [18,19]. LAG3 and CD69 were reported to be in-
duced on certain populations of CD4+CD25− T cells
[20,21] but were scarcely observed on the cell surface
of CD4+CD25+ cells that serve as naturally occurring
regulatory T cells (nTreg) [22]. Indeed, CD4+CD25− T
cells have been recently characterized as the main
source of inducible non-conventional regulatory T cells
[23,24] exerting their suppressive activity via a number
of suppressory molecules including LAG3, CD69, IL-
10, and TGFβ, and by this way promoting exhaustion
of pathogenic T cells, mainly through EGR2-driven
mechanisms [19,21,24,25].There is almost no data describing the role of regula-
tory cell phenotypes and/or inhibitory co-receptors in
the anti-inflammatory effects of cannabinoids. Therefore,
we addressed this question using an in vitro system that
employs interaction of encephalitogenic, MOG35-55
specific T cells (TMOG) with peripheral spleen-derived
APC and naïve accessory T cells.
Antigen presentation to memory/encephalitogenic T cells
is known to lead to activation of several cell cycle and ef-
fector pathways including the phosphatidylinositol-3-kinase/
Akt/mTOR pathway, the mitogen-activated protein kinase
(MAPK) pathway, and the Janus kinase/Signal transduc-
ers and Activators of Transcription (JAK/STATs) path-
way [26,27]. Although Akt and MAPK pathways have
been shown to be targeted by cannabinoids in various im-
mune and non-immune cells [2,28], there is almost no data
regarding the effect of cannabinoids on the activity of these
pathways in inflammatory and autoimmune conditions. In
this regard, we have recently shown that CBD exerts its
anti-inflammatory activity in activated microglial cells via
regulation of STAT1/STAT3 balance [29,30] demonstrating
that STAT family members are targeted by CBD. STAT3
has been described as a key positive regulator of Th17 pro-
liferation and function, including upstream regulation of
RORγt-dependent production of IL-17 [31]. STAT5 is a
major immunoregulatory factor restraining STAT3 pro-
Th17 activity [32]. The ratio between STAT3 and STAT5
has been proposed to serve as a key factor determining the
final pathogenic activity of autoreactive Th17 cells and its
anergic propensity [33]. Moreover, EGR2 has been shown
to act as an essential negative STAT3 regulator including
IL-17 expression and Th17 expansion [34].
Herein, using an in vitro model of stimulated TMOG
cells co-cultured with spleen-derived CD19+ B cells serv-
ing as APC and other accessory CD4+ cells, we investi-
gated the pathways and molecules mediating the
immunoregulatory effects of CBD. The results show that
CBD exerts its immunoregulatory effects via strong up-
regulation of CD69 and of LAG3 inhibitory molecules
on CD4+CD25− T cells. This is accompanied by EGR2,
LAG3, and IL-10-dependent anergy of stimulated auto-
reactive TMOG cells, followed by a shift in STAT3/STAT5
activation ratio leading to decreased Th17-like activity of
CBD-treated memory encephalitogenic T cells observed
by us previously.
Materials and methods
Reagents
Lyophilized MOG35-55 peptide [MEVGWYRSPFSRVVH-
LYRNGK] purchased from GenScript (Piscataway, NJ,
USA) was reconstituted in sterile PBS and the stock solu-
tion stored in aliquots at −20°C. CBD was obtained from
the National Institute on Drug Abuse (Baltimore, MD,
USA) and was dissolved in ethanol. The dose 5 μM of
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in which we showed that CBD at 5 μM significantly inhib-
ited MOG-35-55-induced TMOG cell proliferation and their
Th17-like activity, that is, IL-17 release [8,9]. The final con-
centrations of ethanol in the various experiments did not
exceed 0.1% and had no effect on the results. Fetal calf
serum (FCS) and other tissue culture reagents were ob-
tained from Biological Industries (Kibbutz Beit HaEmek,
Israel).Encephalitogenic T cell line
The MOG35-55-specific T cell line (TMOG) was established
from lymph node cells of C57BL/6 female mice that had
been primed 10 days earlier with MOG35-55 emulsified in
Complete Freund Adjuvant as previously described [5,8].
This TMOG cell line has been maintained in vitro in
RPMI-1640 containing 5% FCS and supplemented with re-
combinant human 10 U/ml of IL-2 (human/mouse cross-
reactive, Peprotech Inc, Rocky Hill, NJ, USA; IL-2 enables
TMOG growth and expansion in between antigen stimula-
tions), 2 mM L-glutamine, 100 μg/ml streptomycin, 100 U/
ml penicillin, 50 μM β-mercaptoethanol, non-essential
amino acids, and 1 mM sodium pyruvate (maintenance
medium) with alternate stimulation with MOG35-55
(5 μg/ml) every 14 days as previously described [5,8].Flow cytometry analysis of immune cell phenotypes
TMOG cells (1 × 10
6 cells) were suspended in 4 ml of
RPMI-1640 containing 2.5% FCS, 100 μg/ml streptomycin,
100 U/ml penicillin, 2 mM L-glutamine, and 50 μM
β-mercaptoethanol (assay medium) and transferred to a
10-cm tissue culture dish. APCs (20 × 106 cells) freshly iso-
lated from spleens of 8-week naïve male C57BL/6 mice
were added, and the mixture (APC/TMOG co-cultures) was
stimulated with 5 μg/ml of MOG35-55. Non-stimulated
and MOG35-55-stimulated APC/TMOG co-cultures were
incubated in 37°C in a 5% CO2 incubator with or without
CBD at 5 μM for 18 h. Then, the cells were spun down
(5 min, 800 × g), the cell pellet resuspended in FACS buffer
(PBS w/o Ca++/Mg++, 1% BSA), incubated with anti-mouse
CD16/CD32 mAb (clone 93; Biolegend, San Diego, CA,
USA), and aliquots of 1 × 106 cells in 0.1 ml were subjected
to staining at 4°C for 30 min using predetermined optimal
concentrations of fluorophore-conjugated antibodies (all
from Biolegend) including: CD4-FITC (H219.19), CD19-
FITC (6D5), MHCII-PE (AF6-120.1), CD25-APC (3C7),
CD69-PE (H1.2 F3), CD69-PE/Cy7 (H1.2 F3), and LAG3-
PE (C9B7W). Staining was followed by two- or four-color
immunofluorescence analysis by flow cytometry. Isotype-
and concentration-matched control antibodies were used
to assess non-specific staining. The cells were examined by
BD LCSII flow cytometer (Becton Dickinson, Franklin
Lakes, NJ, USA) using FACSDiva software (BD).In additional control experiments, freshly isolated
splenocytes were cultured without MOG35-55 (resting
splenocytes), or TMOG cells were cultured without APC
and without MOG35-55 (resting TMOG cells) for 18 h in
the presence or absence of 5 μM CBD in maintenance
medium. After this time, resting splenocytes or resting
TMOG cells were collected and processed by flow cytom-
etry analysis as described above.
CD4+ microbead purification of TMOG cells from APC/TMOG
co-cultures
Dissociated spleen cells were plated in 10-cm plates (50 ×
106 cells/plate) in assay medium. After 2 h at 37°C in 5%
CO2 humidified air to allow APC adherence, the media
with non-adherent cells were removed, and the adherent
APCs were gently washed with Ca++/Mg++ containing PBS
and covered with a new assay medium. Then, 2.5 × 106 of
TMOG cells were added and APC/TMOG co-cultures were
stimulated immediately with 5 μg/ml of MOG35-55 for
8 h in the presence or absence of CBD at 5 μM. CBD was
added just prior to the addition of the MOG35-55. After
8 h of incubation, the media containing mostly TMOG cells
(but not the adherent APC cells) were carefully collected
and spun down for 10 min at 800 × g. The cell pellet was
washed in PBS containing 0.5% BSA and 2 mM EDTA,
centrifuged again and resuspended in 90 μl of this buffer.
To improve the purity of collected cells, CD4 (L3T4) mag-
netic beads (Miltenyi Biotec GmbH, Bergisch Gladbach,
Germany) were added to the cell suspension for positive
selection of CD4+ cells according to the manufacturer in-
structions. The CD4+ cells obtained this way (purified
TMOG cells) were subjected to protein phosphorylation as-
says (by immunoblotting) and to mRNA expression studies
(by qPCR and gene arrays).
The incubation time of 8 h and the 5 μM dose of
CBD were chosen based on previous time- and dose-
response experiments, including cytokine production
and release [9].
CBD effects on signaling pathways
We checked the phosphorylation status of Akt, STAT3,
and STAT5 using appropriate anti-phospho antibodies and
Western blot analysis. The CD4 microbead purified TMOG
cells were rinsed twice with ice-cold PBS and lysed in RIPA
buffer (140 mM NaCl, 20 mM Tris pH 7.4, 10% glycerol,
1% Triton X-100, 0.5% sodium deoxycholate, 0.1% sodium
dodecyl sulfate, 2 mM EDTA) containing protease inhibi-
tor cocktail (1:100, Sigma; St. Louis, MO, USA). Lysates
were centrifuged at 4°C (10 min, 16,000 × g), pellets were
discarded, and the supernatants were aliquoted and stored
at −20°C for further analysis. Protein samples were sub-
jected to 10% SDS-polyacrylamide gel electrophoresis as
described earlier [29]. The blots were incubated overnight
at 4°C with anti-phospho antibodies including: rabbit anti-
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anti-p-STAT3 (Tyr705; Abcam, Cambridge, UK), rabbit
anti-p-STAT3 (Ser727; Cell Signaling), rabbit anti-p-STAT5
(Tyr694; Cell Signaling), as well as mouse anti-total STAT3
protein (Cell Signaling). Horseradish peroxidase (HRP)-
conjugated secondary goat anti-rabbit or anti-mouse anti-
bodies (Jackson ImmunoResearch Laboratories, Inc., West
Grove, PA, USA) were applied for 2 h at room temperature
and the blots visualized using the enhanced chemilumines-
cence detection kit (EZ-ECL, Biological Industries, Kibbutz
Beit Haemek, Israel). The blots were scanned and quanti-
fied with NIH Image 1.63. Levels of β-actin and the total
STAT3 proteins were used as loading controls and for fur-
ther data normalization.
We would like to note that 8 h MOG35-55 stimulation
resulted in a lower yield of encephalitogenic T cells follow-
ing the use of the CD4 microbead system. We assume that
this change in CD4 yield reflects transient downregulation
(internalization and turnover) in CD4 receptor expression
following antigen stimulation [35,36]. Indeed, immunoblot-
ting of STAT3 and β-actin proteins confirmed a decrease in
total level of both of these proteins by about 35% in all
MOG-treated samples. This observation corresponds well
with these previous reports on post-stimulation CD4 recep-
tor downregulation [35,36]. Addition of 5 μM CBD had no
further effect.
RNA extraction, quantitative PCR (qPCR) and microarray
transcript analysis
The Miltenyi CD4 bead purified TMOG cells were lysed and
subjected to RNA extraction (5Prime, Darmstadt, Germany)
followed by qPCR analysis as reported earlier [9]. The cDNA
of each specific gene was amplified using a pair of specific
primers as detailed in Table 1. Quantification was performed
by ‘the comparative cycle of threshold method’ using
β2-microglobulin (β2MG) gene product for normalization
[30]. The qPCR runnings were repeated 3 to 4 times using
mRNA preparations from independent experiments.
For microarray transcripts, 200 ng samples of total RNA
were amplified, labeled and hybridized onto Illumina
MouseRef-8 v 2.0 Expression Bead-Chip (Illumina Inc.,
San Diego, CA, USA), querying the expression of >24,000
RefSeq-curated gene targets and 796 random sequences
(used for the assessment of background noise). ArraysTable 1 Primers used for qPCR analysis of mRNA levels in pur
APCs
Gene Accession number Forward
β2MG NM_009735 AGTTCCACC
STAT5 NM_010118.3 AGTTGTGGA
LAG3 NM_008479.2 CTGCCTTAG
EGR2 NM_010118.3 AGT TGTGG
IL-10 NM_010548.2 CCTTTGCTAwere processed and scanned with Illumina BeadStation
platform according to the manufacturer’s protocol. Raw
data were analyzed using the Bioconductor packages
(http://www.bioconductor.org; [37]).
Statistical analysis
Data is expressed as the mean ± SEM of two to four inde-
pendent experiments and analyzed for statistical significance
using one way analysis of variance (ANOVA), followed by
Newman-Keul’s or Dunnett’s post hoc tests. P < 0.05 was
considered significant. Graph Pad Prism program (La Jolla,
CA, USA) was used for statistical analysis of the data.
Study approval
All mice used in the studies were maintained according
to the guidelines of the Institutional Animal Care and
Use Committee (IACUC). Animal experiments were ap-
proved and performed by the Weizmann Institute of
Science and the Tel Aviv University IACUCs.
Results
CD4+CD25+ cell number is decreased by MOG35-55-
stimulation but not affected by CBD treatment
TMOG cells were co-cultured with splenocytes (APC/TMOG
co-cultures) and stimulated with MOG35-55 at 5 μg/ml
for 18 h in the presence or absence of 5 μM CBD, and the
number of CD4+ cells was determined using flow cytome-
try. As presented in Figure 1A, neither MOG35-55-
stimulation nor CBD addition affected the total number of
CD4+ cells in these co-cultures. Next, we analyzed the fre-
quency of CD4+CD25+ natural regulatory T cells in APC/
TMOG co-cultures (Figure 1B). We observed that in con-
trol, non-stimulated co-cultures 11.0% ± 1.4% of CD4+ cells
were CD25 positive (CD4+CD25+) and this frequency did
not change following CBD treatment (10.4% ± 1.5%;
Figure 1C,D). MOG35-55-stimulation of these APC/TMOG
co-cultures led to a significant decrease in CD4+CD25+
cells (down to 5.5% ± 0.5% of all CD4+, P < 0.05), and this
level was not affected by CBD co-incubation (5.6% ± 0.3%).
CBD induces upregulation of CD4+CD25−CD69+LAG3+
cells in MOG35-55-stimulated APC/TMOG co-cultures
At the second step, we analyzed the CD4+CD25− popula-
tion for the expression of CD69 molecule. In control, non-ified TMOG cells co-cultured previously with adherent
Reverse
CGCCTCACATTGAAA TCGGCCATACTGGCATGCTTAACT
GAGAGAAACAATC ACACCATAGTCAATAAGCCATC
AACATGGGATTC CCATCTCCGTCTCCAGTT
AGAGAGAAACAAT C ACACCATAGTCAATAAGCCATC
TGGTGTCCTTTC GGATCTCCCTGGTTTCTCTT
Figure 1 Decrease in CD4+CD25+ cells in MOG35-55-stimulated APC/TMOG co-cultures is not affected by CBD. Splenocytes (including
accessory CD4+ T cells) were co-cultured with TMOG cells and stimulated with MOG35-55 at 5 μg/ml. CBD at 5 μM was added to the cells
immediately before MOG35-55. (A) Bar graph showing the average percentage of CD4+ cells in APC/TMOG co-cultures (100% as equal to total
number of cells). Neither treatment affected overall CD4+ T cell number; (B) dot plot histogram presenting CD4+ T cells in APC/TMOG co-cultures
positive and negative for CD25 expression; (C) a representative dot plot showing the changes in CD4+CD25+ T cell population in control or
MOG35-55-treated APC/TMOG co-cultures in the presence or absence of CBD; (D) bar graph showing the number of cells positive for CD4 and
CD25 ± SEM. ANOVA F(3,8) = 7.8, P < 0.01. *P < 0.05 vs non-stimulated cells. n = 3 to 4.
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CD4+CD25− cells were found to be positive for CD69
(Figure 2A). Interestingly, 18 h co-incubation with CBD re-
sulted in a very significant increase in CD4+CD25−CD69+
cells reaching 22.5% ± 1.3% (P < 0.001 vs 9.3% ± 0.4% ob-
served in the non-stimulated APC/TMOG co-cultures).
MOG35-55-stimulation of APC/TMOG co-cultures resulted
in doubling the CD69 expression on CD4+CD25− cells up
to 18.0% ± 1.5% (P < 0.001 vs non-stimulated cells), and
CBD addition together with MOG35-55 further increased
the frequency of CD4+CD25−CD69+ cells up to 36.6% ±
1.9% (P < 0.001 vsMOG-treated cells).
Following incubation with CBD, we observed increased ex-
pression of LAG3 regulatory molecule on CD4+CD25− T
cells. The basal number of CD4+CD25− cells expressing
LAG3 (9.7%± 2.6%) was increased by approximately threetimes reaching 29.0%± 2.8% in the presence of CBD
(Figure 2B). MOG35-55 stimulation did not significantly
affect the number of CD4+CD25−LAG3+ cells (13.3%± 3.3%)
as compared to non-stimulated APC/TMOG co-cultures.
Addition of CBD to MOG35-55-stimulated APC/TMOG co-
cultures resulted in a similar level of increase in LAG3 as ob-
served in non-stimulated cells (reaching 29.6%± 2.7% of the
total CD4+CD25− cells; Figure 2B).
Co-expression of CD69 and LAG3 molecules on CD4+
CD25− T cells has been defining an inducible non-
classical regulatory T cell phenotype [25]. The number of
CD4+CD25− cells double positive for CD69 and LAG3 in
control APC/TMOG co-cultures was 1.1% ± 0.9% of the
total CD4+CD25− cells and this frequency was not signifi-
cantly affected in the presence of CBD (3.1% ± 2.7%;
Figure 2C,D). MOG35-55 stimulation of APC/TMOG co-
Figure 2 CBD treatment results in upregulation of CD69 and of LAG3 regulatory molecules on CD4+CD25− T cells in MOG35-55-
stimulated APC/TMOG co-cultures. APC/TMOG co-cultures were treated with MOG35-55 and CBD. (A) Percentage of CD4
+CD25− T cells
expressing CD69 (ANOVA F(3,12) = 68.9; P < 0.001); (B) percentage of CD4+CD25− T cells expressing LAG3 (ANOVA F(3,12) = 13.0, P < 0.001); (C) the
representative contour plot density graphs showing the co-expression of CD69 and LAG3 in the CD4+CD25− subpopulation; (D) percentage of
CD4+CD25− cells expressing both CD69 and LAG3 ± SEM. ANOVA F(3,7) = 7.3, P < 0.05. *P < 0.05, **P < 0.01, ***P < 0.001 vs non-stimulated cells;
#P < 0.05, ##P < 0.01, ###P < 0.001 vs MOG35-55-stimulated cells. n = 3 to 4.
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CD25−CD69+LAG3+ cells (2.1% ± 1.5%). However, CBD
treatment led to a three-fold increase in CD4+CD25−
CD69+LAG3+ cells, reaching 6.8% ± 2.6% (P < 0.05) in
MOG35-55-treated cells (Figure 2C,D).
As controls, we analyzed the effects of CBD treatment
on the expression of CD69 and of LAG3 on resting spleno-
cytes cultured without TMOG and without MOG35-55 as
well as in resting TMOG cultured without MOG35-55 and
without APC (both in maintenance medium). These con-
trol experiments showed that the levels of CD69 (6.9% ±
1.2%) and of LAG3 (0.5% ± 0.3%) in resting spleen-derived
CD4+ splenocytes cultured separately were not signifi-
cantly affected by CBD treatment (reaching 8.7% ± 1.7%
and 0.4% ± 0.4%, respectively; Table 2). Similarly, in restingTMOG cells cultured alone, CBD treatment did not affect
the basal levels of CD69 (0.9% ± 0.3% in control cells and
1.0% ± 0.2% in CBD-treated) and of LAG3 (0.7% ± 0.2%
and 0.5% ± 0.1%, respectively). These experiments demon-
strate that the changes in CD69 and LAG3 expression are
induced by CBD treatment only in APC/TMOG co-cultures
and not in TMOG or in splenocytes cultured separately.
mRNA levels of anergy-associated genes are upregulated
in MOG35-55-stimulated TMOG cells and enhanced by CBD
CD4+CD25− T cells expressing CD69 and/or LAG3 have
been shown to be potent inducers of anergy in activated
effector/memory T cells via upregulating EGR2 tran-
scription factor [16,17]. Thus, we examined the levels of
EGR2 mRNA in non-stimulated and in MOG35-55-
Table 2 CBD treatment does not affect CD69, CD25, and
LAG3 expression in resting cells
Phenotype Control (%) CBD (%) T test
Resting splenocytes
CD4+ 20.0 ± 2.7 20.7 ± 2.2 ns
CD4+CD69+ 6.9 ± 1.2 8.7 ± 1.9 ns
CD4+LAG3+ 0.5 ± 0.3 0.4 ± 0.4 ns
CD19+ 59.4 ± 2.0 59.4 ± 2.1 ns
CD19+CD69+ 13.6 ± 3.4 17.4 ± 3.4 ns
CD19+CD25+ 2.5 ± 0.2 3.1 ± 0.2 ns
Resting TMOG cells
CD69+ 0.9 ± 0.3 1.0 ± 0.2 ns
LAG3+ 0.7 ± 0.2 0.5 ± 0.1 ns
Freshly isolated mouse splenocytes (including accessory CD4+ T cells and
CD19+ B cells) or resting TMOG cells were maintained separately for 18 h in
maintenance medium without MOG35-55 and in the presence or absence of
CBD at 5 μM. CD69, LAG3 and CD25 surface expression was analyzed using
flow cytometry (n = 3). Data are expressed as percentage ± SEM defined as the
percent of cells expressing relevant antigen within an appropriate
parent population.
ns, not significant.
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APC.
TMOG cells were activated with MOG35-55 for 8 h in
the presence of adherent APC. The floating TMOG cells
were then collected and purified using CD4 microbeads
and their mRNA subjected for qPCR analysis of EGR2
mRNA. We found that MOG35-55 stimulation dramat-
ically upregulated the expression of EGR2 mRNA in the
purified TMOG cells as compared to control cells
(P < 0.01; Figure 3A). This effect was potentiated by
CBD treatment by another 25% (P < 0.05). CBD itself
slightly but insignificantly increased the expression of
EGR2 mRNA in non-stimulated TMOG cells.
In parallel, we have evaluated the mRNA levels of other
anergy promoters including STAT5 transcription factor,
LAG3, and the IL-10 anti-inflammatory cytokine. Figure 3B
shows that MOG35-55 stimulation increased STAT5
mRNA in TMOG cells (by twofold; P < 0.05). CBD did not
have any further effect on MOG35-55-upregulated STAT5
mRNA expression. CBD did not affect the basal STAT5
levels either (Figure 3B). Interestingly, CBD significantly
upregulated (by ca fivefold) the level of LAG3 mRNA in
control, non-stimulated TMOG cells previously co-cultured
with adherent APC (P < 0.01; Figure 3C). Stimulation with
MOG35-55 led to a very high LAG3 mRNA upregulation
(by ca tenfold, P < 0.001). Moreover, the amount of LAG3
mRNA expression was further increased in the presence of
CBD by additional 120% (P < 0.001; Figure 3C). In the case
of IL-10, neither CBD addition nor MOG35-55 stimulation
affected the level of IL-10 mRNA expression (Figure 3D).
However, CBD treatment of MOG35-55-stimulated cells
resulted in a significant IL-10 mRNA upregulation of 100%above the level observed in MOG35-55-treated TMOG cells
(P < 0.01; Figure 3D).
We performed gene array analysis of mRNA expression
in TMOG cells in search for additional transcripts that are
involved in anergy and tolerogenic processes. As shown in
Table 3, MOG35-55-stimulation of TMOG cells led to a sig-
nificant upregulation of various anergy promoters repre-
senting the following categories: regulators of cell cycle
(Ndrg1 by 6.2-fold, Cdkn1a by 2.6-fold, Casp4 by 2.2-fold,
and Fas by 2.6-fold), tolerance inducers (Lag3 by 1.7-fold,
Icos by 1.6-fold, Nfatc1 by 3.3-fold), and chemokine recruit-
ing regulatory T cells (Ccl4 by 9.1-fold). The addition of
CBD treatment significantly potentiated the MOG35-55-
upregulated transcript levels of tolerance inducers, that is,
of Lag3 (by 305%), Icos (by 43%), and Nfatc1 (by 21%) and
of cell cycle regulators such as Cdkn1a (by 19%), Casp4 (by
22%), and Fas (by 27%). It did not affect the MOG35-55-
enhanced levels of Ndrg1 and Ccl4. Treatment with CBD
alone resulted in more than twofold increase of the levels of
Icos, Ndrg1, and Casp4 in non-stimulated TMOG cells (P <
0.005). Slight but significant increases were observed fol-
lowing CBD treatment for Lag3, Nfatc1, and Fas mRNA
transcripts in non-stimulated TMOG cells.
Th17 signature signaling pathways are affected by CBD in
TMOG cells co-cultured previously with APC
EGR2 was previously reported to control STAT3 and
STAT5 activities, the main respective positive and negative
regulators of Th17 phenotype [33]. Therefore, we evaluated
the levels of STAT3 and STAT5 activation in TMOG cells.
As described above, TMOG cells co-cultured with adherent
spleen-derived APCs were stimulated with MOG35-55 in
the presence or absence of 5 μM CBD. After 8 h of stimu-
lation, CD4 microbead purified TMOG cells were lysed, sub-
jected to gel electrophoresis, and immunostained for
phospho-STAT3 (at Tyr705 and Ser727) and for phospho-
STAT5 (at Tyr694).
A relatively high amount of STAT3 phosphorylated at
Tyr705 (a major activating residue) as well as at Ser727 (en-
hancing STAT3 dimerization, translocation to the nucleus
and DNA binding) was observed in TMOG cells even with-
out stimulation with MOG35-55 (Figure 4A,B,E). MOG35-
55 stimulation led to a small, but significant, increase
in the levels of phospho-STAT3 at both Tyr705 (by
20%, P < 0.05) and Ser727 (by 32%, P < 0.001). CBD
treatment led to a large decrease in Tyr705 phospho-
STAT3 in both non-stimulated (reduction by 67%) and
stimulated TMOG cells (reduction by 68%; P < 0.001).
CBD decreased slightly, but significantly (by 15%,
P < 0.05), the phosphorylation of STAT3 at position
Ser727 in non-stimulated TMOG cells and had a
larger effect (decrease of 35%, P < 0.001) on Ser727
phosphorylation in the presence of MOG35-55
(Figure 4B,E).
Figure 3 The effect of CBD treatment on EGR2, STAT5, LAG3, and IL-10 mRNA levels in purified TMOG previously co-cultured with APC.
TMOG cells were co-cultured with adherent APC and stimulated with MOG35-55 in the presence or absence of CBD. TMOG cells were then purified
using CD4+ microbeads, lysed, and subjected for mRNA extraction and qPCR analysis using gene specific primers. The bar graphs show the levels
of the indicated mRNAs as percentage of the amounts observed following stimulation with MOG35-55. (A) EGR2 mRNA (ANOVA F(3,4) = 211.5,
P < 0.001); (B) STAT5 mRNA (ANOVA F(3,12) = 6.1, P < 0.01); (C) LAG3 mRNA (ANOVA F(3,8) = 116.5, P < 0.001); (D) IL-10 mRNA (ANOVA F(3,11) = 9.9,
P < 0.01); (n = 2 to 4). Symbols: *P < 0.05, **P < 0.01, ***P < 0.001 vs non-stimulated cells; #P < 0.05, ##P < 0.001, ###P < 0.001 vs MOG35-55-stimulated cells.
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stimulation increased STAT5 phosphorylation (at Tyr694).
CBD addition to non-stimulated TMOG cells resulted in in-
creased phospho-STAT5 levels (by 24%, P < 0.05), MOG35-
55 stimulation resulted in increased phospho-STAT5 levels
of 30% (P < 0.01). Applying MOG35-55 and CBD together
resulted in an additive effect of 60% (P < 0.01, Figure 4D,E).
The Akt pathway is known to positively regulate ef-
fector T cells’ proliferation while restraining intracellularTable 3 mRNA microarray analysis of CBD and MOG35-55 mo
Gene Full name MO
Lag3 Lymphocyte-activation gene 3 1.7
Icos Inducible T-cell costimulator 1.6
Nfatc1 Nuclear factor of activated T-cells, cytoplasmic 1 3.3
Ndrg1 N-myc downstream-regulated gene 1 6.2
Cdkn1a Cyclin-dependent kinase inhibitor 1A 2.6
Casp4 (Casp11) Caspase 4, apoptosis-related cysteine peptidase 2.2
Fas Fas cell surface death receptor 2.6
Ccl4 Chemokine (C-C motif) ligand 4 9.1
TMOG/adherent APC co-cultures were stimulated with MOG35-55 in the presence or
subjected to microarray analysis. The table presents the genes significantly upregul
expressed as fold change vs purified TMOG cells that were not stimulated by MOG35
CBD vs the MOG35-55-induced effect. Values in italics indicate significant effects ofregulatory mechanism [27]. Indeed, phospho-Akt levels
were increased by 57% (P < 0.001) in stimulated TMOG
cells co-cultured previously with APC. CBD treatment
decreased Akt phosphorylation by 25% (P < 0.001;
Figure 4C,E). Moreover, CBD treatment also decreased
phospho-Akt levels in non-stimulated TMOG cells by
20% (P < 0.05).
We performed control experiments to evaluate if
CBD treatment affects the activity of STAT3, STAT5,dulation of TMOG cell activity
G (fold change) MOG + CBD (fold change) CBD (fold change)
5.2 1.7
2.3 2.1
4.0 1.3
6.7 2.5
3.1 1
2.7 2.1
3.3 1.3
9 0.9
absence of CBD. mRNA from CD4+ microbead purified TMOG cells was
ated by MOG35-55 and their modulation by CBD (P < 0.005). The data are
-55 when co-cultured with APC. Numbers in bold indicate significant effect of
CBD vs non-stimulated TMOG cells (P < 0.005).
Figure 4 CBD modulates Th17 signaling pathways in TMOG cells co-cultured with spleen-derived APC. Pre-adhered APC were co-cultured
with TMOG cells and stimulated with MOG35-55 in the presence or absence of CBD. CD4
+ microbead purified TMOG cells were lysed and proteins
subjected to gel electrophoresis, followed by transfer to nitrocellulose membrane and immunostaining of the phosphorylated forms of Akt,
STAT3, and STAT5 as well as of total amount of β-actin and STAT3. The bar graphs show average percentage values (in comparison to MOG35-55
without CBD as 100%) of (A) phospho-STAT3 Tyr705 (ANOVA F(3,4) = 94.3, P < 0.001); (B) phospho-STAT3 Ser727 (ANOVA F(3,4) = 96.7, P < 0.001),
(C) phospho-Akt (ANOVA F(3,4) = 96.7, P < 0.001); (D) phospho-STAT5 (ANOVA F(3,7) = 32.6, P < 0.001); (E) representative blots showing the
phosphorylated forms of Akt, STAT3 (Tyr705 and Ser727), and STAT5 Tyr694 as well as total levels of β-actin and STAT3 (n = 2 to 3); (F) in this
control experiment, resting TMOG cells were cultured without APC and without MOG35-55 for 8 h in the presence or absence of 5 μM CBD in
maintenance medium. Representative immunoblots (n = 2) show that CBD does not affect the levels of phospho-Akt, phospho-STAT3, and
phospho-STAT5 in resting TMOG cells cultured without APC. Symbols: *P < 0.05, **P < 0.01, ***P < 0.001 vs non-stimulated purified TMOG;
##P < 0.001,
###P < 0.001 vs MOG35-55-treated TMOG cells.
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maintenance medium without MOG35-55 stimulation
and without splenocytes. Figure 4F shows that CBD
did not affect the phospho-STAT3 (Tyr705, Ser727),
phospho-Akt, and phospho-STAT5 levels in these rest-
ing TMOG cells.The expression of MHCII, CD25, and CD69 on CD19+ B
cells is downregulated following CBD treatment in
MOG-stimulated APC/TMOG co-cultures
LAG3 increases were found to reduce APC functions, in-
cluding antigen presentation by MHCII molecules [12].
Indeed, MHCII expression is an important parameter in
Kozela et al. Journal of Neuroinflammation  (2015) 12:52 Page 10 of 16determining the antigen presenting efficiency of cells, in-
cluding B cells, the main peripheral APC. We have, there-
fore, examined if the CBD-induced increase in LAG3 is
accompanied by changes in CD19+ B cell APC activities.
We found that neither MOG35-55 nor CBD treatments
affected the total number of CD19+ B cells in APC/TMOG
co-cultures (Figure 5A). CD19high B cells were observed to
be upregulated in autoimmune pathologies and proposed
to be targeted in therapeutic approaches [38]. Indeed, we
observed that 18 h MOG35-55 stimulation of APC/TMOG
co-cultures resulted in a significant increase in the number
of CD19highMHCIIhigh cells (35.5% ± 5.0% of all CD19+
MHCII+ cells), reaching almost twice the level observed in
control, non-stimulated cells (18.0% ± 0.8%; Figure 5B,
C,D). Co-incubation of MOG35-55-stimulated APC/
TMOG cells with 5 μM of CBD resulted in a large decrease
of CD19highMHCIIhigh cells back to the basal level of
22.0% ± 2.0% (P < 0.05). CBD did not affect the number of
CD19highMHCIIhigh cells in non-stimulated, control APC/
TMOG co-cultures (20.9% ± 1.5%; Figure 5D).
CD25 antigen (that is, IL2 receptor α) is recognized as
a marker of CD19+ B cells autoimmune activity and is
involved in cytokine secretion [39]. We observed that
the frequency of CD19+CD25+ cells was as low as 2.5%
± 0.2% of the total CD19+ B cell population in resting
naïve spleen-derived APC cells cultured without enceph-
alitogenic TMOG (Table 2). However, the CD19
+CD25+Figure 5 Upregulation of MHCII in CD19high B cells in MOG35-55-stim
co-cultures were stimulated with MOG35-55, treated with CBD and the per
(A) Neither treatment affected the number of CD19+ B cells; (B) dot plot sh
expressing MHCII; (C) representative dot plot graph of CD19highMHCIIhigh c
CD19highMHCIIhigh B cells within the total CD19+MHCII+ cells (taken as 100%
MOG-stimulated cells. n = 3.frequency increased to 34.3% ± 7.2% following co-
culturing of splenocytes with TMOG cells (Figure 6B,C).
CBD did not affect the number of CD19+CD25+ cells in
non-stimulated APC/TMOG co-cultures (30.2% ± 5.1%).
On the other hand, MOG35-55 stimulation of APC/
TMOG co-cultures resulted in a significant increase in
CD19+CD25+ cells (up to 54.8% ± 2.4% of the total
CD19+ cells, P < 0.01), and this number was decreased in
the presence of CBD to 41.6% ± 2.5% (P < 0.05 vs
MOG35-55-stimulated cells) (Figure 6B,C).
CD69 level on CD19+ B cells serves as an indication of
B cells pro-inflammatory activity. In spleen-derived APC
cultured without TMOG cells (resting splenocytes),
13.6% ± 3.4% of the CD19+ B cells are CD69 positive and
this expression is not significantly affected by CBD treat-
ment (17.4% ± 3.4%; Table 2). However, co-culturing of
spleen-derived APC cells with TMOG cells resulted in a
remarkable increase in CD69 antigen, particularly on
CD19high B cells as this population reached 44.2% ± 2.6%
of all CD19+CD69+ cells (Figure 7B,C). CBD co-
incubation decreased the number of CD19highCD69high
in non-stimulated APC/TMOG co-cultures down to
21.6% ± 5.9% (P < 0.01). MOG35-55 stimulation of APC/
T co-cultures resulted in a further significant increase in
CD19highCD69high frequency reaching 70.0% ± 1.0% of
the total number of CD19+ cells (P < 0.01). This increase
was reduced in the presence of CBD to 45.2% ± 6.9% - aulated APC/TMOG co-cultures is decreased by CBD. APC/TMOG
centage of CD19highMHCIIhigh B cells determined using flow cytometry.
owing representative flow cytometry gating of CD19+ B cells
ells; (D) bar graph showing the mean ± SEM percentage of
). ANOVA F(3,8) = 7.6, P < 0.05. *P < 0.01 vs control, #P < 0.01 vs
Figure 6 Upregulation of CD19+CD25+ B cells in MOG35-55-stimulated APC/TMOG co-cultures is decreased by CBD. APC/TMOG co-cultures
were treated as described above and cells were stained and analyzed by flow cytometry. (A) Dot plot showing gating for CD19+CD25+ cells; (B)
density gradient graphs for CD25 expression on CD19+ cells; (C) bar graph showing the mean percent ± SEM of CD19+ B cells expressing CD25.
ANOVA F(3,8) = 8.8, P < 0.01 with 100% representing total CD19+ cells. **P < 0.01 vs non-stimulated cells, #P < 0.01 vs MOG35-55-stimulated
cells. n = 3.
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APC/TMOG co-cultures (Figure 7B,C).LAG3 expression on CD19+ B cells is not affected by the
presence of CBD
Although LAG3 serves as a CD4 negative co-receptor
and thus is mainly expressed on CD4+ T cells, its in-
creased levels have been recently reported on B cells as
well [40]. In our hands, the basal frequency of CD19+
LAG3+ B cells in APC/TMOG co-cultures was only
6.9% ± 0.4% and was not affected by the presence of
CBD (7.9% ± 0.9%; Table 4). Moreover, neither MOG35-
55 stimulation nor MOG+CBD combination had any
effect on CD19+LAG3+ cell frequencies in our APC/
TMOG co-cultures (6.0% ± 0.4% and 5.7% ± 0.9%, re-
spectively). Thus, in contrary to the situation in T cells,LAG3 expression in B cells is not regulated by either
MOG35-55 stimulation or CBD treatment.Discussion
In this work, we studied the immunoregulatory effects
of CBD using an in vitro model of TMOG cells co-
cultured with spleen derived APCs and other accessory
cells. We found that CBD exerts its immunoregulatory
effects by a de novo induction of regulatory CD4+CD25−
T cells that express high levels of suppressive CD69 and
LAG3 molecules. This induction was accompanied by
an increase in EGR2 transcription, as well as EGR2 and
IL-10-dependent anergy of stimulated memory TMOG
cells and in a shift in STAT3/STAT5 activation balance.
Moreover, we observed decreased antigen presenting
capabilities (indicated by lower MHCII expression) and
Figure 7 MOG35-55 increases and CBD decreases the number
of CD19+CD69+ B cells in APC/TMOG co-cultures. APC/TMOG
co-cultures were examined for CD19+CD69+ cells using flow cytometry.
(A) Dot plot graph showing gating for CD19+CD69+ cells; (B)
representative dot plots showing flow cytometry analysis of CD69
expression on CD19+ B cells with a quadrant marking
CD19highCD69high cells; (C) bar graph showing the mean
percentages ± SEM of CD19highCD69high within CD19+CD69+ parent
population (equivalent to 100%). ANOVA F(3,8) = 19.3, P < 0.001.
**P < 0.01 vs control, ##P < 0.01 vs MOG-stimulated cells. n = 3.
Table 4 Level of LAG3 expression on CD19+ B cells in the
presence of CBD in APC/TMOG co-cultures
Treatment CD19+LAG3+ (%)
Control 6.9 ± 0.4
CBD 7.9 ± 0.9
MOG35-55 6.0 ± 0.4
CBD +MOG35-55 5.7 ± 0.9
APC/TMOG co-cultures were stimulated with MOG35-55 and CBD. The level of
LAG3 was measured by flow cytometry and is expressed as mean ± SEM% of
CD19+ B cells positive for LAG3. ANOVA F(3,8) = 1.8, P > 0.05 (n = 3).
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CD69 and CD25 expression) of MOG35-55-stimulated B
cells in the presence of CBD (Scheme 1).
Naturally occurring CD4+CD25+ regulatory T cells
(nTreg) play an indispensable role in preventing auto-
immunity mostly via Foxp3-dependent transcription [41].
Reduced frequency and reduced suppressive functions of
nTreg (for example, via impaired STAT5 activity) have
been observed in MS patients [42,43]. This phenomenonwas mimicked in our in vitro autoimmune model in which
MOG35-55 stimulation resulted in reduced number of
CD4+CD25+ nTreg cells, demonstrating the suitability of
this system for studying autoimmune inflammation and
for identifying possible treatments. Interestingly, CBD did
not reverse the MOG35-55-induced reduction in CD4+
CD25+ nTreg cells. Thus, we assume that other regula-
tory mechanisms mediate the anti-inflammatory activity
of CBD in this system and in Th17-driven EAE.
Non-classical CD4+ T regulatory cells are induced in
the periphery and have a pivotal role in maintaining im-
mune tolerance, mainly via Foxp3-independent mecha-
nisms. CD4+CD25− T cells have been reported to be the
main source of inducible regulatory phenotypes [23,24].
These cells exert their regulatory functions via a number
of unique surface regulatory molecules, including LAG3
and CD69, acting separately or synergistically to dimin-
ish inflammation, including Th17-driven autoimmunity
[19,44]. Such immunoregulation involves impaired anti-
gen stimulation of T memory cells, impaired interactions
of memory T cells with APC, promoting negative shift in
Teff/Treg balance and/or inducing anergy in activated T
cells. Our results show that CBD treatment upregulates
the levels of CD69 as well as of LAG3 molecules on
CD4+CD25− T cells (splenocytes) co-cultured with TMOG
cells. Moreover, in MOG35-55-stimulated APC/TMOG
co-cultures, CBD effect was augmented and led to the
induction of regulatory phenotypes double positive for
CD69 and LAG3, suggesting boosted immunoregulation
upon self-antigen activation.
CD69 was shown to serve as a constitutive brake for
Th17 differentiation [18,19]. CD69 has a negligible ex-
pression in resting T and B lymphocytes but is rapidly
induced on these cells upon their activation [45]. CD69
was initially considered as an early activation marker
and its key role in inducing regulatory mechanisms is
well documented [18,46,47]. Although CD69 deficiency
does not affect basal lymphocyte function, it leads to
augmented autoimmunity including murine collagen-
induced arthritis, lupus, or autoimmune myocardiopathy
([48]; see [18] for additional refs). Indeed, CD69-
deficient naïve T cells preferentially differentiate toward
Scheme 1 Schematic diagram showing the main effects of CBD (in red) in MOG35-55-stimulated APC/TMOG co-cultures. The symbols
used in the scheme are explained below.
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stimulation in vitro and in vivo that is accompanied by
increased STAT3/RORγt and diminished STAT5 activ-
ities [19]. In agreement with this, CD69 induction was
shown to increase STAT5 suppressory activity and to
decrease IL-17 release [19]. These observations are in
line with our results showing that CBD upregulates
CD69 on CD4+CD25− T cells and that CBD treatment
leads to decreased STAT3 and increased STAT5 phos-
phorylations in TMOG cells.
LAG3 is similar to CD4 in its structure and genomic
organization and serves as a high affinity, negative
competitor of CD4 in binding MHCII [49,50]. LAG3
plays a crucial role in immune homeostasis involving
antigen-stimulated T cells and has become a golden
standard in tracking regulatory T cell phenotypes in
many species, including human [44,51]. Interestingly,
similarly to the case of CD69, LAG3 deficiency does
not result in basal lymphocyte dysfunction but rather im-
pairs tolerogenic mechanisms upon antigen activation
leading to exacerbated autoimmunity. Basal levels of LAG3
in quiescent immune cells are low and this level is in-
creased in activated T cells, including Th17 subtype, as a
negative feedback loop response [20,49,50,52,53].
LAG3 was shown to reduce antigen-induced T cell ex-
pansion, to limit memory T cell pools [13], and toprevent various types of autoimmunity in mice
[52,54-56]. LAG3 increased expression on regulatory
cells has been accompanied by decreased IL-17 and in-
creased IL-10 secretions [24,51,57]. Thus, the increase
of LAG3 by CBD treatment reported here is in agree-
ment with our previous results showing that CBD
lowers IL-17 expression and secretion [9].
Increased LAG3 and IL-10 expressions are the most
reliable markers of ongoing EGR2-driven anergic pro-
cesses in activated T cells [24,25,57-59]. Forced expres-
sion of EGR2 in naïve T cells converts them into
LAG3 expressing and IL-10 secreting regulatory cells
[25] while EGR2 deficiency results in lupus-like auto-
immunity [60], as well as increased STAT3 phosphor-
ylation and IL-17 secretion [34]. Indeed, here we
show that CBD treatment, that, as discussed above,
decreases IL-17 secretion [9] promotes expression
of EGR2 in TMOG cells along with enhanced expres-
sion of LAG3 and IL-10 as well as of STAT5
phosphorylation.
Anergy-related decrease in T cell division and cytokine
secretion (exhaustion) is driven by a well-defined set of
tolerogenic genes and inhibitory proteins activated in re-
sponse to antigen stimulation and is increased via EGR2
activation [16,61,62]. Accordingly, our gene transcript
analysis of the effect of CBD on stimulated TMOG cells
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number of transcripts are known to execute cell cycle ar-
rest and EGR2-dependent tolerogenic events [16,62-64].
Several of these transcripts were found by us to be upreg-
ulated when CBD was added together with MOG35-55,
including NFATc1, Casp4, Ndrg1, Lag3, and Icos. In
addition, Akt activation, known for its role in restraining/
reversing anergy [27,65] was upregulated by MOG35-
55-activation and reduced in the presence of CBD, add-
ing to the anergy-facilitating environment induced by
this cannabinoid.
MHCII-dependent APC function of B cells is required
for the induction of MOG35-55-induced Th17 differen-
tiation, memory T cells’ expansion and EAE develop-
ment [66]. B cells are the main source of IL-6 cytokine
that controls Th17 differentiation [11]. Indeed, defi-
ciency in IL-6-secreting B cells prevents IL-17 produc-
tion and EAE [67]. This corresponds well with our
recent observations that CBD decreases IL-6 and IL-17
release from stimulated TMOG cells as well as lowers
EAE severity [8,9]. Increased LAG3 was shown to impair
antigen presenting functions of immune cells [68]. Thus,
CBD-induced increase in LAG3 levels could lead to the
reduced antigen presenting capacities in B cells as in-
deed indicated by lower MHCII levels in our system,
along with the reduction in their pro-inflammatory ac-
tivity as indicated by the lower levels of CD25 and
CD69, molecules that serve as signature markers for B
cell autoimmune activation [39,69].
Interestingly, the CBD-induced shift in STAT3/STAT5
phosphorylation ratio, the decrease in Akt activity in
TMOG cells as well as the increases in CD69 and LAG3
expression on accessory T cells are also observed in
APC/TMOG co-cultures in the absence of MOG35-55
stimulation. This suggests that CBD may be raising an
inherent basal activation threshold in these encephalito-
genic T cells. Clearly, CBD-induced immunosuppression
is amplified under activation conditions as evidenced by
the induction of CD4+CD25−CD69+LAG3+ cell popula-
tion in CBD-treated MOG35-55-stimulated APC/TMOG
co-cultures, accompanied by EGR2-dependent anergy in
TMOG cells co-treated with CBD and MOG35-55. More-
over, by changing the balance of STAT3/STAT5 tran-
scription factors and by increasing IL-10 expression in
stimulated TMOG cells, CBD seems to turn pathogenic
Th17 into non-pathogenic or even anti-inflammatory T
cells. This phenomenon is known as a STAT5-
dependent cytokine switch of memory T cells and has a
self-regulatory function [70,71]. It may involve inhibition
of neighboring cells, such as APC [72].
Conclusions
Cannabinoid regulation of immune cell function was
studied and reviewed by several other groups [1,2,73,74].Various cannabinoids have been shown to decrease mat-
uration, proliferation, migration, adhesion, and cytokine
secretion from activated immune cells. Our group and
others identified MAPKs, AP-1, NFkB, STAT, and NFAT
pathways as well as ROS formation to be targeted by
cannabinoids in activated immune cells [1,2,30,73,74].
However, most of the data addressing these pathways
was obtained with the use of naïve immune cells acti-
vated by non-specific activators, like phytohaemagluti-
nin, PMA/Ionomycin, and/or bacterial endotoxins, that
only to a limited extent mimic the in vivo inflammation,
particularly of autoimmune background. Moreover, al-
though cell-mediated immunoregulation has been
proved to be the most effective way of restoring immune
homeostasis, the effect of cannabinoids on cell-mediated
immunoregulation has been barely investigated so far.
Recent work of Hegde et al. [75] showed that myeloid-
derived suppressor cells may mediate anti-inflammatory
effects of CBD in autoimmune hepatitis suggesting that
cannabinoids indeed have a potential to involve regula-
tory cells in their anti-inflammatory effects. Here, we are
using an in vitro model, composed of memory T cells
stimulated with myelin antigen in the presence of per-
ipheral accessory cells to study the complex multicellular
interactions driving the autoimmune inflammation and
to study the effects of CBD on these processes. This ap-
proach mimics much better the in vivo autoimmune
processes that take place in EAE mice. Our in vitro sys-
tem allowed us to show that CBD anti-inflammatory ac-
tivities in autoimmune conditions involve de novo
induction of regulatory phenotypes, transcriptional and
functional reprogramming of memory T cells toward
non-pathogenic and even inhibitory cells (increased IL-
10), as well as reduced activation of B cells, the main
antigen presenting cells in the periphery.
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